new glp 1 agonist novo nordisk Oral Semaglutide Approved to Reduce the Risk of Cardiovascular Events Novo Nordisk's oral GLP-1 drug

Bray et al., 2021

Childhood obesity in India: A two-decade meta-analysis of prevalence and socioeconomic correlates

In the context of MASLD/MASH, analogous rebound phenomena would be expected: regression of achieved steatosis resolution and potential re-emergence of inflammatory activity and fibrogenic stimuli upon drug withdrawal

New members starting a GLP-1 for weight loss must have a BMI of 40 or higher to qualify for coverage

Randomised controlled trial of fish oil supplementation on responsiveness to resistance exercise training in sarcopenic older women

Both lixisenatide (79) and liraglutide (80) have also been reported to increase chylomicron triacylglycerol clearance